208 related articles for article (PubMed ID: 29462558)
1. Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody.
Prantner AM; Yin C; Kamat K; Sharma K; Lowenthal AC; Madrid PB; Scholler N
Mol Pharm; 2018 Apr; 15(4):1403-1411. PubMed ID: 29462558
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of (111)In labeled antibodies for SPECT imaging of mesothelin expressing tumors.
Misri R; Saatchi K; Ng SS; Kumar U; Häfeli UO
Nucl Med Biol; 2011 Aug; 38(6):885-96. PubMed ID: 21843785
[TBL] [Abstract][Full Text] [Related]
3. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
Garg G; Gibbs J; Belt B; Powell MA; Mutch DG; Goedegebuure P; Collins L; Piwnica-Worms D; Hawkins WG; Spitzer D
BMC Cancer; 2014 Jan; 14():35. PubMed ID: 24447304
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
6. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.
Rump A; Morikawa Y; Tanaka M; Minami S; Umesaki N; Takeuchi M; Miyajima A
J Biol Chem; 2004 Mar; 279(10):9190-8. PubMed ID: 14676194
[TBL] [Abstract][Full Text] [Related]
7. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.
Tang Z; Feng M; Gao W; Phung Y; Chen W; Chaudhary A; St Croix B; Qian M; Dimitrov DS; Ho M
Mol Cancer Ther; 2013 Apr; 12(4):416-26. PubMed ID: 23371858
[TBL] [Abstract][Full Text] [Related]
8. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.
Scholler N; Garvik B; Hayden-Ledbetter M; Kline T; Urban N
Cancer Lett; 2007 Mar; 247(1):130-6. PubMed ID: 16677756
[TBL] [Abstract][Full Text] [Related]
9. TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
Park GB; Kim D
Oncol Rep; 2017 Nov; 38(5):3167-3176. PubMed ID: 28901470
[TBL] [Abstract][Full Text] [Related]
10. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
[TBL] [Abstract][Full Text] [Related]
11. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors.
Hung CF; Calizo R; Tsai YC; He L; Wu TC
Vaccine; 2007 Jan; 25(1):127-35. PubMed ID: 16930783
[TBL] [Abstract][Full Text] [Related]
12. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo targeting imaging of pancreatic cancer using a Fe3O4@SiO2 nanoprobe modified with anti-mesothelin antibody.
Liu F; Le W; Mei T; Wang T; Chen L; Lei Y; Cui S; Chen B; Cui Z; Shao C
Int J Nanomedicine; 2016; 11():2195-207. PubMed ID: 27274243
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of Mesothelin-Specific Ligands for SPECT Imaging of Triple-Negative Breast Cancer.
Montemagno C; Bacot S; Ahmadi M; Kerfelec B; Baty D; Debiossat M; Soubies A; Perret P; Riou L; Fagret D; Broisat A; Ghezzi C
J Nucl Med; 2018 Jul; 59(7):1056-1062. PubMed ID: 29572256
[TBL] [Abstract][Full Text] [Related]
15. Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway.
Huo Q; Xu C; Shao Y; Yu Q; Huang L; Liu Y; Bao H
Int J Biol Sci; 2021; 17(2):574-588. PubMed ID: 33613114
[No Abstract] [Full Text] [Related]
16. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
[TBL] [Abstract][Full Text] [Related]
17. Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells.
Hung CF; Tsai YC; He L; Wu TC
Gene Ther; 2007 Jun; 14(12):921-9. PubMed ID: 17377599
[TBL] [Abstract][Full Text] [Related]
18. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer.
Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H
Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000
[TBL] [Abstract][Full Text] [Related]
19. Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.
Su Y; Tatzel K; Wang X; Belt B; Binder P; Kuroki L; Powell MA; Mutch DG; Hawkins WG; Spitzer D
Oncotarget; 2016 May; 7(21):31534-49. PubMed ID: 27120790
[TBL] [Abstract][Full Text] [Related]
20. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.
Sato N; Hassan R; Axworthy DB; Wong KJ; Yu S; Theodore LJ; Lin Y; Park L; Brechbiel MW; Pastan I; Paik CH; Carrasquillo JA
J Nucl Med; 2005 Jul; 46(7):1201-9. PubMed ID: 16000290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
